Company Filing History:
1 out of 13 
1 out of 15 Years Active: 2025
Title: Qingshan Zhang: Innovator in Cancer Treatment
Introduction
Qingshan Zhang is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of cancer treatment through his innovative research and development of binding moieties that target Claudin18.2.
Latest Patents
Qingshan Zhang holds a patent for "Claudin18.2 binding moieties and uses thereof." This patent describes binding moieties, such as antibodies, that specifically bind to Claudin18.2. It also includes chimeric antigen receptors comprising these binding moieties. Furthermore, the patent provides engineered immune cells, such as T cells, that incorporate anti-Claudin 18.2 chimeric antigen receptors. The methods disclosed in this patent aim to treat Claudin18.2-expressing tumors or cancers using the binding moieties, chimeric antigen receptors, and engineered immune cells. He has 1 patent to his name.
Career Highlights
Qingshan Zhang has worked with notable companies in the biotechnology sector, including Nanjing Genscript Biotech Co., Ltd. and Nanjing Legend Biotech Co., Ltd. His work in these organizations has contributed to advancements in cancer therapies and immunology.
Collaborations
Some of his notable coworkers include Liusong Yin and Tielin Zhou. Their collaborative efforts have further enhanced the research and development of innovative cancer treatments.
Conclusion
Qingshan Zhang is a key figure in the field of cancer treatment, with a focus on Claudin18.2 binding moieties. His contributions through patents and collaborations have the potential to significantly impact cancer therapies.